I've been browsing through "The supplement to the journal of the american academy of dermatology"(what a name!) for the 3-7 march meeting.
You cand download it here
It contains all poster exhibits that have been presented at this AAD meeting. It's 28Mb with 275 pages.
Look at this:
Investigating rosacea in the National Ambulatory Medical Care Survey
Aditya Gupta, MD, PhD, MBA, Department of Medicine, Sunnybrook and
Women’s College Health Sciences Center (Sunnybrook site) and the University
of Toronto, Toronto, ON, Canada; Mediprobe Research Inc., London, ON,
Canada; Elizabeth Cooper, Alek Hunchak, Mediprobe Research Inc., London,
Rosacea is a common, chronic inflammatory disorder affecting roughly 10% of the
population. It may lead to significant cosmetic damage and can result in a diminished
quality of life if untreated. As there is no cure for rosacea, physicians treat
with a wide variety of medications. While topical metronidazole is the single most
common treatment, numerous other options, including topical agents, oral antibiotics,
and steroids, are also prescribed. A retrospective, cross-sectional study of data
from the National Ambulatory Medical Care Survey was used to interpret treatment
trends for rosacea between the years of 1993 and 2002. The NAMCS data are a
nationally representative survey containing weighted data on office visits to
physicians in the United States. Data were analyzed with SPSS and the R language.
Overall, approximately 13.4 million patients with rosacea visited physicians in the
United States during the reporting period, 4.7 million of which were diagnosed only
with rosacea, and no other conditions. The majority of diagnosed patients were
female (69.4%), and the average age of patients was 51.1 years. Topical metronidazole
was the single most commonly used treatment, given to approximately 46.7% of
these patients. Topical and oral antibiotics were given at 59.4% and 46.4% of visits,
respectively, and given in combination at 24.5% of patient visits. Steroids (5.4% of
patients) and retinoids (1.5%) were used infrequently. Approximately 8.6% of
patients received no medication. The most common comorbid conditions existing
with rosacea included ‘‘actinic keratoses’’ (1.14 million patients), ‘‘seborrheic
dermatitis’’ (662,000), and ‘‘essential hypertension’’ (307,000). The weighted data
suggest that over 350,000 children under the age of 15 years had a diagnosis of
rosacea. Few publications in the medical literature discuss the epidemiology of
rosacea in children and use of rosacea medications in children. More information is
needed to prepare physicians for pediatric patients presenting with a potential case
Author disclosure: Nothing disclosed at press time.
Commercial support: None.